Susquehanna International Group’s Indivior Pharmaceuticals INDV Stock Holding History

Susquehanna International Group’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.03M	Sell	165,000 -819,800	-83%	-$27.1M	﹤0.01%	4211
2025 Q4	$35.3M	Buy	984,800 +92,000	+10%	+$2.81M	﹤0.01%	1664
2025 Q3	$21.5M	Buy	892,800 +856,800	+2,380%	+$17.9M	﹤0.01%	2122
2025 Q2	$531K	Buy	+36,000	New	+$419K	﹤0.01%	9045
2025 Q1	–	Sell	-21,300	Closed	-$265K	–	12941
2024 Q4	$265K	Sell	21,300 -48,100	-69%	-$495K	﹤0.01%	10101
2024 Q3	$677K	Sell	69,400 -89,900	-56%	-$1.05M	﹤0.01%	7735
2024 Q2	$2.57M	Buy	+159,300	New	+$2.88M	﹤0.01%	4599

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's INDV Position: Q1 2026 in Review

Susquehanna International Group increased its Indivior Pharmaceuticals (INDV) stake by 229% in Q1 2026, buying an estimated $3.68M and bringing the position to 160,097 shares worth $4.88M. The position accounts for ﹤0.01% of the portfolio, ranked #4270.

Susquehanna International Group first reported a position in INDV in Q3 2023 and has held it in 11 quarters since. The position peaked at $21.7M in Q1 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

Susquehanna International Group held 160,097 shares of Indivior Pharmaceuticals worth $4.88M as of Q1 2026.
Susquehanna International Group bought 111,412 Indivior Pharmaceuticals shares in Q1 2026, an estimated $3.68M.
Indivior Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4270 holding.
Susquehanna International Group first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Susquehanna International Group's Indivior Pharmaceuticals position peaked at $21.7M in Q1 2025.
289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.